These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


172 related items for PubMed ID: 24965902

  • 1. Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.
    Al Therwani S, Mose FH, Jensen JM, Bech JN, Pedersen EB.
    BMC Nephrol; 2014 Jun 25; 15():100. PubMed ID: 24965902
    [Abstract] [Full Text] [Related]

  • 2. Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects.
    Al Therwani S, Rosenbæk JB, Mose FH, Bech JN, Pedersen EB.
    BMC Nephrol; 2017 Mar 13; 18(1):86. PubMed ID: 28288570
    [Abstract] [Full Text] [Related]

  • 3. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB.
    BMC Nephrol; 2017 Aug 15; 18(1):268. PubMed ID: 28810844
    [Abstract] [Full Text] [Related]

  • 4. Effect of volume expansion with hypertonic- and isotonic saline and isotonic glucose on sodium and water transport in the principal cells in the kidney.
    Jensen JM, Mose FH, Bech JN, Nielsen S, Pedersen EB.
    BMC Nephrol; 2013 Sep 26; 14():202. PubMed ID: 24067081
    [Abstract] [Full Text] [Related]

  • 5. Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
    Mose FH, Larsen T, Jensen JM, Hansen AB, Bech JN, Pedersen EB.
    Scand J Clin Lab Invest; 2014 Jan 26; 74(1):8-19. PubMed ID: 24256611
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.
    Mose FH, Larsen T, Jensen JM, Hansen AB, Bech JN, Pedersen EB.
    Br J Clin Pharmacol; 2014 Oct 26; 78(4):789-99. PubMed ID: 24697877
    [Abstract] [Full Text] [Related]

  • 9. The effect of sodium nitrite infusion on renal function, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamide in healthy subjects: a randomized, double-blinded, placebo-controlled, crossover study.
    Rosenbaek JB, Pedersen EB, Bech JN.
    BMC Nephrol; 2018 Sep 21; 19(1):244. PubMed ID: 30241504
    [Abstract] [Full Text] [Related]

  • 10. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
    Matthesen SK, Larsen T, Vase H, Lauridsen TG, Jensen JM, Pedersen EB.
    Clin Exp Hypertens; 2013 Sep 21; 35(5):313-24. PubMed ID: 22966789
    [Abstract] [Full Text] [Related]

  • 11. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC.
    Am J Physiol Renal Physiol; 2006 Feb 21; 290(2):F273-8. PubMed ID: 16189291
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.
    Hew-Butler T, Hummel J, Rider BC, Verbalis JG.
    Am J Physiol Regul Integr Comp Physiol; 2014 Aug 15; 307(4):R366-75. PubMed ID: 24944242
    [Abstract] [Full Text] [Related]

  • 13. Effects of sodium nitrite on renal function and blood pressure in hypertensive vs. healthy study participants: a randomized, placebo-controlled, crossover study.
    Rosenbæk JB, Hornstrup BG, Jørgensen AN, Mortensen J, Pedersen EB, Bech JN.
    J Hypertens; 2018 Mar 15; 36(3):666-679. PubMed ID: 29065098
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Direct effect of methylprednisolone on renal sodium and water transport via the principal cells in the kidney.
    Lauridsen TG, Vase H, Bech JN, Nielsen S, Pedersen EB.
    Eur J Endocrinol; 2010 May 15; 162(5):961-9. PubMed ID: 20203161
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls.
    Jensen JM, Mose FH, Kulik AE, Bech JN, Fenton RA, Pedersen EB.
    BMC Nephrol; 2014 Jun 26; 15():101. PubMed ID: 24970686
    [Abstract] [Full Text] [Related]

  • 18. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS, Nakamura H, Murata M, Kuroda K, Suzuki H, Yokoyama Y, Shimada A, Matsushita S, Yamamoto T, Amano A.
    BMC Cardiovasc Disord; 2016 Sep 13; 16(1):181. PubMed ID: 27624603
    [Abstract] [Full Text] [Related]

  • 19. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
    Tamma G, Di Mise A, Ranieri M, Geller A, Tamma R, Zallone A, Valenti G.
    J Cell Mol Med; 2017 Sep 13; 21(9):1767-1780. PubMed ID: 28326667
    [Abstract] [Full Text] [Related]

  • 20. Protein-enriched diet increases water absorption via the aquaporin-2 water channels in healthy humans.
    Lauridsen TG, Vase H, Starklint J, Bech JN, Pedersen EB.
    Nephrol Dial Transplant; 2010 Aug 13; 25(8):2502-10. PubMed ID: 20237060
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.